Emergent Biosolutions
EBS
275 hedge funds and large institutions have $2.79B invested in Emergent Biosolutions in 2018 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 91 increasing their positions, 106 reducing their positions, and 25 closing their positions.
56% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 25
45% more call options, than puts
Call options by funds: $3.22M | Put options by funds: $2.22M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
30% more capital invested
Capital invested by funds: $2.15B → $2.79B (+$642M)
5% more funds holding
Funds holding: 263 → 275 (+12)
0.63% less ownership
Funds ownership: 85.45% → 84.83% (-0.63%)
14% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 106
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$57.1M |
| 2 |
Neuberger Berman Group
New York
|
+$19.6M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$18M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.8M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$9.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$29M |
| 2 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$19.7M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$16.8M |
| 4 |
Man Group
London,
United Kingdom
|
-$14.8M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$14.7M |
EBS Hedge Fund Activity: Q3 2018 in Review
275 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2018, worth a combined $2.79B — up 30% from $2.15B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new EBS positions and 25 closed out — a net gain of 14 holders — while 91 added to existing stakes and 106 trimmed.
The largest buyer was BlackRock, adding an estimated $57.1M. The largest seller was Millennium Management, exiting entirely with an estimated $29M sold.
- 275 institutional investors held Emergent Biosolutions (EBS) as of Q3 2018, up from 263 in Q2 2018.
- Funds reported $2.79B of Emergent Biosolutions stock for Q3 2018, up 30% quarter-over-quarter.
- 39 funds opened new Emergent Biosolutions positions in Q3 2018 and 25 closed out, a net change of +14 holders.
- The largest Emergent Biosolutions buyer in Q3 2018 was BlackRock, an estimated $57.1M added.
- The largest Emergent Biosolutions seller in Q3 2018 was Millennium Management, an estimated $29M sold.
Based on aggregated 13F filings for Q3 2018.